A retrospective study on the therapeutic effect of tocilizumab on COVID-19

A retrospective study on the therapeutic effect of tocilizumab on COVID-19 - J-COVID-RT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040614

Enrollment

Registered

2020-06-01

Start date

2020-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A case diagnosed as COVID-19 and administered tocilizumab

Exclusion criteria

Exclusion criteria: Cases where tocilizumab administration was judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
Survival rate	—

Secondary

Measure	Time frame
1) Time until the RT-PCR becomes negative in the pharyngeal swab or nasopharyngeal swab (calculated for the first hospitalization date, symptom onset date, and diagnosis date) 2) Fever duration 3) Improvement rate of image findings 4) Number of days until improvement of image findings is confirmed 5) Time required until each of supplemental oxygen / non-invasive ventilation or high-flow oxygen therapy (Nasal high flow) / invasive mechanical ventilation by endotracheal intubation / ECMO (starting date: 1st hospitalization date), Symptom occurrence date, and, Diagnosis date are calculated respectively), the number of days of implementation 6) Hospitalization days 7) Survival period (calculation dates are calculated for 1st hospitalization, 2nd symptom onset, and 3rd diagnosis) Exploratory analysis: 1) Predictors of treatment effect 2) Clinical course, age, sex, medical history, smoking history, complications, blood sampling test results, therapeutic agents other than tocilizumab	—

Measure

Time frame

1) Time until the RT-PCR becomes negative in the pharyngeal swab or nasopharyngeal swab (calculated for the first hospitalization date, symptom onset date, and diagnosis date) 2) Fever duration 3) Improvement rate of image findings 4) Number of days until improvement of image findings is confirmed 5) Time required until each of supplemental oxygen / non-invasive ventilation or high-flow oxygen therapy (Nasal high flow) / invasive mechanical ventilation by endotracheal intubation / ECMO (starting date: 1st hospitalization date), Symptom occurrence date, and, Diagnosis date are calculated respectively), the number of days of implementation 6) Hospitalization days 7) Survival period (calculation dates are calculated for 1st hospitalization, 2nd symptom onset, and 3rd diagnosis) Exploratory analysis: 1) Predictors of treatment effect 2) Clinical course, age, sex, medical history, smoking history, complications, blood sampling test results, therapeutic agents other than tocilizumab

—

Countries

Japan

Contacts

Public ContactTakehiro Izumo

Japanese Red Cross Medical Center Department of Respiratory Medicine

izumo_takehiro@med.jrc.or.jp03-3400-1311

Outcome results